Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer

Yanmeizhi Wu1, Shan Yu2* and Hong Qiao1*

1Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, 2Department of Pathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

immune checkpoint inhibitors, inflammatory factors, programmed death-1, immune-related adverse events, tumor microenvironment

1 Introduction

Immunotherapy modulates the body’s immune system to fight immune evasion and immune silencing of tumors. Immune checkpoint inhibitors (ICIs) have the effect of stimulating activation and proliferation on T cells, so it is more beneficial to destroy tumor cells. Currently available immune checkpoint inhibitors are mainly programmed death-1 (PD-1) and its ligand (PD-L1), targeting cytotoxic T lymphocyte antigen-4 (CTLA-4). Further ICIs are being discovered and studied (Parry et al., 2005; Rosenberg et al., 2016), such as Lymphocyte Activation Gene-3 and T cell immunoglobulin mucin-3. Responses to ICIs have only been observed in certain solid tumors, such as gastrointestinal
malignancies and unresectable or metastatic melanoma. And it is often accompanied by the possibility of resistance to ICIs (Haslam and Prasad, 2019; Puccini et al., 2020). The major reasons that account for diverse responses to ICIs are the contributions of multiple components of the tumor microenvironment (TME), including immune cells, fibroblasts, and the extracellular matrix (ECM). Thus, the interaction of inflammatory factors with components in the TME modulates responses to ICIs from different perspectives.

The number of patients being treated with ICIs is increasing, and thus cases of immune-related adverse events (irAEs) are also reported in a wide range of organs (June and Bluestone, 2017; Poto et al., 2022). Although the presence of irAEs is generally believed to be associated with better responses to ICIs, unpredictable and uncontrollable irAEs are a major obstacle preventing a complete course of ICIs therapy. The types of inflammatory factors involved in different irAEs are different, and the inflammatory factors associated with different therapeutic targets are not the same (Teulings et al., 2015; Berner et al., 2019). In addition, the discordance of inflammatory factors in TME and irAEs has also led to a new hypothesis that inflammatory factors mediate different signaling pathways involved in tumor response to ICIs and triggering of tissue-specific irAEs.

We aim to highlight the role of inflammatory factors in the TME on the response to ICIs, and also to address the involvement of inflammatory factors in the occurrence of irAEs.

2 Inflammatory factors on response to immune checkpoint inhibitors in the tumor microenvironment

Research on immune checkpoints has shown that most of them act as “brakes” in immune function, i.e., ICIs reactivate T cells to more effectively clear cancer cells (Ljunggren et al., 2018). At present, ICIs widely used in clinical applications mainly include anti-PD-1/PD-L1 and anti-CTLA-4. Additional immune checkpoint molecules are under study (Bagchi et al., 2021). The combination of PD-L1 and PD-1 will accelerate the apoptosis of immune cells, especially those with PD-1 positive. CTLA-4 also inhibits T cell activity and is up-regulated upon T cell activation (Valk et al., 2008). However, PD-L1 was a predictor for the response to ICIs rather than CTLA-4. One classification of TME is based on tumor-infiltrating lymphocytes (TILs) and PD-L1 expression, which are the main predictors of response to ICIs (Powles et al., 2014). Among them, one type with PD-L1 positive and abundant TIL infiltration had the best response to ICIs treatment (Teng et al., 2015). Furthermore, cancer ECM influences the response to immunotherapy through secreted regulators and suppressors (Umair et al., 2018; Bagaev et al., 2021). The ECM status provides important complementary information on the capture capacity of T cells (Mariathasan et al., 2018) and is considered a major common denominator of anti-ICIs (Jensen et al., 2021). Among them, cancer-associated fibroblasts (CAFs) are involved in constituting ECM fibrosis to hinder T cell infiltration and T cell activity, which produces a marked effect on immunotherapy resistance (Wang et al., 2018a; Mariathasan et al., 2018). The following summarizes the effects of inflammatory factors on the response of ICIs in TME from three aspects: PD-L1 abundance, TIL density, and ECM status (Figure 1).

2.1 Inflammatory factors regulating programmed death ligand-1 abundance

The abundance of PD-L1 in TME could predict therapeutic response to ICIs in multiple cancers, such as melanoma (Caroline et al., 2015) and cancer in lung (Borghaei et al., 2015) and bladder (Rosenberg et al., 2016). Inflammatory-related signaling was confirmed to regulate the expression of PD-L1 (Ji et al., 2015) but was detected not only on T cells (Fehrenbacher et al., 2016). PD-L1 is commonly detected by adaptive and innate immune cells, as well as epithelial cells, especially under inflammatory conditions (Sharpe et al., 2007). Many classical inflammatory factors have a hand in the regulation of PD-L1, which are discussed below respectively.

2.1.1 Interferons

Interferons (IFNs) are secreted in large quantities by various activated immune cells, mainly by T cells and natural killer cells (NK cells). Importantly, PD-L1 of target cells can be triggered by IFN-γ (Garcia-Diaz et al., 2017). T cells secreted IFN-γ through the JAK1/JAK2-STAT1/STAT3 pathway (Karachaliou et al., 2018; Na et al., 2018; Thiem et al., 2019; Fujita, 2021). The JAK1/JAK2-STAT1 pathway has also been observed to stimulate IFN-γ secretion in NK cells (Bellucci et al., 2015). Further, IFN-γ receptor can also stimulate JAK-STAT, and STAT1 signaling is preferred (Plataniou, 2005). In contrast, IFN-γ induces protein kinase D isoform 2 (PKD2), an important isoform that inhibits PD-L1 and promotes a strong antitumor immune response (Chen et al., 2012). Silencing of Male Germ Cell Associated Kinase (MAK), CRK Like Proto-Oncogene (CRKL) and PI3K signaling pathways also impair PD-L1 depending on IFN-γ (Garcia-Diaz et al., 2017). In melanoma, nuclear factor-xB(NF-xB) signal is required for IFN-γ to upregulate PD-L1 ( Gowrishankar et al., 2015). Furthermore, IFN-γ receptor 1 inhibition can reduce PD-L1 expression in acute myeloid leukemia mice through the MEK-ERK and myeloid differentiation factor88 (MYD88)-tumor necrosis factor receptor-associated factor6 (TRAF6) pathways (Abiko et al., 2015). Since IFN-γ of TME is generally considered to be beneficial for immunotherapy, tumor cells may undergo survival-stressed proliferation when the IFN-γ signaling pathway is defective (Abril-Rodriguez and Ribas, 2017).
is one of the currently recognized causes of adaptive resistance during immunotherapy (Yi et al., 2018). Thus, an intact IFN-γ signaling pathway is a determinant for robust antitumor effects that persist throughout the course of ICIs treatment. It is worth noting that the close relationship between IFN-γ levels and PD-L1 was not necessarily observed in all cell types. For example, when sarcoma mice were treated with an IFN-γ blocking antibody, PD-L1 was largely abolished on tumor cells but not on tumor-associated macrophages (Noguchi et al., 2017). Therefore, more studies on the interaction of IFN-γ and PD-L1 need to be carried out.

IFN-α/β also induces PD-L1 in cancer cells, endothelial cells and leukocytes (Schreiner et al., 2004; Eppihimer et al., 2015; Garcia-Diaz et al., 2017). IFN-α sensitizes the STAT1 signal, further increasing PD-L1 (Meng et al., 2020). However, there are limited reports on the correlation of IFN-α/β with response to ICIs, which may be due to the small effect of IFN-α/β on PD-L1 directly.

2.1.2 Toll-like receptors

Toll-like receptors (TLRs) family, secreted by both myeloid cells and lymphocytes (Loke and Allison, 2003; Gang et al., 2013), connect innate immunity and adaptive immunity. On the one hand, PD-L1 expression is regulated by TLR4 through MyD88-dependent or MyD88-independent pathways (Lu et al., 2008). Besides, TLR4 activates the downstream NF-κB signaling pathway through transforming growth factor kinase 1 (TAK1) and activates the MAPK pathway through the transcription factor AP-1 (Qian et al., 2008). On the other hand, IFN-α production is activated by TLR4 ligands in plasmacytoid dendritic cells (PDCs) (Zhang et al., 2020). TLR3 can also cause increased PD-L1 expression in DCs (Pulko et al., 2009), endothelial cells (Cole et al., 2011) and neuroblastoma cells (Boes and Meyer-Wentrup, 2015) under conditions stimulated by polyinosinic:polycytidylic acid. However, the relevant mechanism is still unclear.

2.1.3 Interleukin (ILs)

Interleukin (ILs) are a class of lymphokine that interacts between immune cells. On the one hand, a number of ILs upregulate PD-L1 on immune cells, including IL-10 (Cole et al., 2011) and IL-17 (Zhao et al., 2011) in monocytes, IL-4 (Ou et al., 2012) and IL-6 (Kim et al., 2008) in dendritic cells. IL-1β upregulates PD-L1 via the NF-κB (Kondo et al., 2010), and IL-27 via STAT1 and
STAT3 signaling pathways (Karakhanova et al., 2011). In addition, IL-2, 7, 15 and 21 also increased PD-L1 in vitro (Kinter et al., 2008). On the other hand, IL in tumor cells can also cause high PD-L1, like IL-4, IL-17 in prostate and colon cancer cells (Wang et al., 2017), IL-27 in ovarian cancer cells (Carbotti et al., 2015), IL-10 in myelodysplastic syndrome blasts (Kondo et al., 2010), renal cell carcinoma (Quandt et al., 2014). IL-12-mediated regulation of PD-L1 may be more complex because IL-12 raises PD-L1 protein level rather than transcription (Mezzadra et al., 2017). (CMTM)4/6 present on the cell surface binds to PD-L1 on macrophages while lowering PD-L1 when IFN-γ lacking (Xiong et al., 2014).

2.1.4 Other factors

Transforming growth factor (TGF)-β production by CD8+ T cells was required for cells to consistently express PD-L1 (Baas et al., 2016). Meanwhile, TGF-β induced DCs to express PD-L1 in vitro in lung cancer (Ni et al., 2012) and hepatocellular carcinoma (Song et al., 2014), respectively. Tumor necrosis factor (TNF)-α in endothelial cells was observed to be relevant to high PD-L1 (Mazanet and Hughes, 2002). More reports are in autoimmune diseases such as Paget’s disease (Iga et al., 2019) and rheumatoid arthritis (Wasén et al., 2018). The regulation of PD-L1 expression by these promising inflammatory factors in the TME and further clarification of their roles in response to ICI therapy are warranted. In addition, CKLF (Chemokine-like factor)-like MARVEL transmembrane domain containing (CMTM)4/6 present on the cell surface binds to PD-L1 on protein level rather than transcription (Mezzadra et al., 2017).

2.2 Inflammatory factors regulating tumor-infiltrating lymphocyte density

Along with PD-L1 positivity, tumors respond well to ICIs when TILs are abundant and show drug resistance otherwise (Na et al., 2018). Thus, TIL density acts as a predictor of response to treatment with ICIs, too. It has been found that abundant TILs are associated with both adaptive upregulation of PD-L1 and the clinical benefit of immunotherapy (Xing et al., 2018). Pre-existing TILs are liberated by PD-L1/PD-L1 inhibitors and then promote tumor regression (Yagi et al., 2017; Tomioka et al., 2018). However, TILs on response to anti-CTLA-4 therapy is controversial. Baseline TIL status before treatment has been reported to predict a good therapeutic effect in melanoma (Chen et al., 2016), but no prognostic benefit has also been observed (Huang et al., 2011). Although anti-CTLA-4 is not prominent in immunotherapy as a monotherapy, it is being clinically tested in a variety of cancers as an effective means of enhancing anti-tumor response when applied with other therapies, such as chemotherapy and radiotherapy. This section focuses on those inflammatory factors and immune cells in the TME that attract or reject homing T cells and thus positively or negatively correlate with ICI responses.

2.2.1 Tumor-infiltrating lymphocyte cells associated with immune checkpoint inhibitor responsiveness

TCRs (T cell receptors) are massively amplified in metastatic pancreatic cancer following anti-CTLA-4 (Hopkins et al., 2018). Within the TME, the enrichment of T cells with the same TCR is a hallmark of effective treatment with ICI therapy (Ro et al., 2017; Arakawa et al., 2019). CD8+ T cells are regarded as the key to "stem cell-like" antitumor immunity due to their unique expression of the transcription factor TCF1 (Siddiqui et al., 2019). After ipilimumab, those patients with CD45RA- had better responses, both for CD4+ T and CD8+ T cells (Subrahmanym et al., 2018). In a study of nivolumab in non-small cell lung cancer, 18% of patients (23/126) exhibited complete or partial responses after treatment. Responders had more CD62LlowCD4+ T cells in the predose circulation than non-responders (Kagam et al., 2020). Similar results in metastatic melanoma had shown that 9 of the 32 patients responded to ICIs. More memory CD4+ T cells were in the cancer tissues of the 9 responders, which were not only related to the expression of CD62L, but also to CCR7 and CD28 (Sade-Feldman et al., 2019). Therefore, the frequency of pre-treatment TIL populations and their dynamic changes may serve as important predictive biomarkers for distinguishing between ICI responders and non-ICI responders.

2.2.2 Inflammation factors related to T cell homing

Chemotactic cytokines are a class of small cytokines that induce the orientation of responding cells into the site of infection during the immune response. Some chemokines are themselves pro-inflammatory factors, such as IL-8 (Maekawa et al., 2022), while others are regulated by inflammatory factors (Figure 2). Chemokine CC receptor (CCR) 7 binds to its selectin ligand, and chemotactic mature T cells migrate to specific targets. The phenomenon of immune desertification in the TME is a consequence of CCR7 deficiency (Berghuis et al., 2011). The expression of chemokine CC ligand (CCL) 5 is guided by IFN-α and gathers T cells in prostate cancer (Harlin et al., 2009). When triggering WNT/b-catenin, CCL4 downregulation results in failure of effector T cell recruitment and activation (Stefani et al., 2015). Both TLR4 and IL-6 levels were positively correlated with chemokine CXC receptor (CXCR) 3 expression, which may regulate the infiltration of CD8+ T cells (Muthuswamy et al., 2016). In tumor-infiltrating PDCs, CXCR4 is regulated to activate the TNF-α through NF-κB (Han et al., 2021). Inhibition of IFN-γ-induced SDF-1/MIP-1α pathway also reduces CXCR4 and CCR5 (Creery et al., 2004). The chemokine CXC ligand (CXCL) 9 and CXCL10 also contributed to the infiltration of TILs (Liu et al., 2015; Peng et al., 2015). STAT3 signaling can downregulate the CX3CR/CXCL10 axis in CD8+ T cells (Yue et al., 2015), thereby reducing
their ability to penetrate the TME. CXCL9 and CXCL10 can be activated via IFN-α to promote TILs increasing in the cancer of the prostate gland (Harlin et al., 2009). CXCL11 was correlated with TLR4 levels positively (Muthuswamy et al., 2016). Regardless of tumor subtype, T cells from breast cancer patients treated with anti-PD-1 were clonally expanded, mediated CD8+ T cell homing via CXCL13, and attracted CD4+ T cells by CXCR5 (Bassez et al., 2021). In addition, CCR5, CCL2, CCL3, CCL11 and CX3CL1 were also positively associated with T cell infiltration (Peng et al., 2015; Manou et al., 2020; Bassez et al., 2021).

However, chemokines do not always work as expected (Bassez et al., 2021). A study of patients with metastatic urothelial carcinoma who received PD-L1 blocker found that TILs could not reach the tumor center and were trapped in the surrounding matrix (Mariathasan et al., 2018). Tumor-derived chemokines are one of the main reasons for misdirecting activated T cells to the stromal cells surrounding the tumor. For example, stromal cells surrounding pancreatic tumors produce CCL12, which attracts effector T cells and prevents them from entering the tumor core (van der Woude et al., 2017). The CXCL9/CXCR3 axis may also have a dual role in promoting T cell migration and tumor cell metastasis (Billottet et al., 2013). High expression of CCL2, CCL22, and CXCL12 normally attracts immunosuppressive cells (Harlin et al., 2009). For non-small cell lung cancer, CCL2 blockade reduces immunosuppression and enhances cancer immunotherapy (Fridlender et al., 2010).

The TGF-β has been concerned due to its negative impact on T cells. Blocking the TGF-β signaling pathway contributes to the transition of the TME to an immune-inflammation-rich state, which has significant advantages in tumor control when combined with ICI (Mariathasan et al., 2018; Ravi et al., 2018). Moreover, stimulation of PD-1/PD-L1 by TGF-β receptor (TGF-βRII) results in a reduction in the host’s rejection of the graft, suggesting that similar processing may also be involved in the TME (Baas et al., 2016).

2.2.3 Regulatory immune cells

Several regulatory immune cells influence TIL infiltration (Gabrilovich, 2017; Mantovani et al., 2017) (Table 1), mainly including regulatory T (Treg) cells, myeloid-derived suppressor cells (MDSCs) and monocytes. Tregs can either restrict the amount of effector T cells by depleting IL-2 (Setoguchi et al., 2005) or inhibit the function of effector T cells by producing TGF-β and IL-10 (Takahashi et al., 1998; Camisaschi et al., 2010). In turn, TGF-β and IL-10 expand Treg cells (Chen et al., 1994). In addition, Treg cells produce perforin and granzymes to kill effector T cells (Mantovani et al., 2017). Activated Treg cells express LAG-3 (Huang et al., 2004) and CTLA-4, which promote indoleamine 2,3-dioxygenase (IDO) secretion (Mellor and Munn, 2004), thereby causing T cell dysfunction (Uyttenhove et al., 2003). Small numbers of Tregs are associated with increased ICIs response and patient survival (Read et al., 2006; Friedline et al., 2009). In bladder cancer patients, however, CTLA-4 blockade resulted in an increased proportion of Tregs (Liakou et al., 2008). This suggests that the baseline status of immune cells and ICIs-related changes are of different predictive significance and that effector T cells/Treg ratio may be a more effective method for predicting response to treatment with ICIs (Sharma et al., 2021). Significantly, the effect of anti-CTLA-4 depends on antibody-dependent cytotoxic activity (ADCC) to deplete CTLA-4-expressing Treg cells in the TME, and its deletion...
will abolish the anti-tumor effect of anti-CTLA-4 (Bulliard et al., 2013; Selby et al., 2013). PD-1 inhibitors on Treg cells remain unclear.

Correlations between MDSCs abundance and response to ICIs have been revealed in numerous clinical trials (Meyer et al., 2014; Weber et al., 2016). MDSCs suppress the immune system by expressing PD-L1 (Noman et al., 2014), secreting IL-10 and TGF-β (Hart et al., 2011; Trikha and Carson3rd, 2014), and recruiting Tregs with CD40 (Pan et al., 2010). MDSCs impede response to ICIs not only with ipilimumab (Liakou et al., 2008) but also with anti-PD-L1 therapy (McDermott et al., 2018). MDSCs can reduce T cell reactivity (Messmer et al., 2015). In renal cell cancer, the inhibition of STAT3 aggregates MDSC, further leading to T cell suppression (Ko et al., 2009). MDSCs abolish the directional migration of CD8+ T cells when upregulated by NADPH oxidase (Nagaraj et al., 2007; Lu et al., 2011). Decreased recruitment and differentiation of MDSCs through obstruction of COX-2/PGE2 resulted in improved CTL frequency and immune responses (Obermajer et al., 2011). The combined use of CSF-1R inhibition and CXCR2 antagonism can also reduce the number of MDSCs and improve anti-PD-1 efficacy (Kumar et al., 2017a). Targeted drugs that inhibit the recruitment of tumor-infiltrating CXCR2+ MDSCs can enhance the response of ICIs (Sun et al., 2019). The combined use of CSF-1R inhibition and CXCR2 antagonism can also reduce the number of MDSCs and improve anti-PD-1 efficacy (Kumar et al., 2017a). Targeted drugs that inhibit the recruitment of tumor-infiltrating CXCR2+ MDSCs can enhance the response of ICIs (Sun et al., 2019). In addition, inhibition of MDSCs by the DNA demethylating agent 5-aza-2'-deoxycytidine also promotes antitumor immune responses (Daurkin et al., 2010).

Increased frequency of circulating monocytes at baseline predicts better ICI response (Martens et al., 2016; Krieg et al., 2018). Macrophages, granulocytes and DCs are of importance. The phagocytic capacity of tumor-associated macrophages (TAMs) is regulated by the PD-1/PD-L1 (Gordon et al., 2017). Differentiation of PD-1+ TAMs impairs effector T cell function (Li et al., 2019). Type 1 polarization (TAM-1) of TAMs is prevented by blocking leukocyte immunoglobulin-like receptor B2 (LILRB2), which improves anti-PD-L1 responses (Chen et al., 2018). CD47 blockade increases the efficiency of anti-PD-L1 in melanoma to by modulating the activity of TAMs (Sockolosky et al., 2016). Tumor-associated neutrophils (TANs) can be divided into type 1 (TAN-1) and type 2 (TAN-2), the former stimulating infiltration of effector T cells (Eruslanov et al., 2014) and the latter an immunosuppressive phenotype (Singhal et al., 2016). Increased eosinophils contribute to the polarization of macrophages in favor of TAM-1, which is further mediated by CCL5, CXCL9 and CXCL10 (Carretero et al., 2015). Conversely, basophils attract CD8+ T cells in the TME by producing CCL3 and CCL4 (Sektioglu et al., 2016). Differentiation of peripheral DCs also modulates the response to anti-PD-1 (Bolton et al., 2015).

### TABLE 1 Regulation of TIL infiltration by Regulatory immune cells.

| Inflammatory factors | Outcomes | References |
|----------------------|----------|------------|
| APC Treg             | Depletion of IL-2 | Inhibiting the proliferation of effector T cell | Setoguchi et al. (2005) |
|                      | Expression of LAG-3 | Inhibiting the activation of T cell | Huang et al. (2004) |
|                      | TGF-β, IL-10 | Killing effector T cells | Takahashi et al. (1998), Camisaschi et al. (2010) |
|                      | IDO | | Mellor and Munn (2004) |
|                      | Perforin, granzyme | | Mantovani et al. (2017) |
| MDSCs                | STAT3 | Promoting the expression of PD-L1 | Ko et al. (2009) |
|                      | NADPH | Inhibiting the migration of T cell | Naganaj et al. (2007) |
|                      | COX-2/PGE-2 | Inhibiting T cell reactivity | Obermajer et al. (2011) |
|                      | Arginase, iNOS | | Orillion et al. (2017), ChristmasEntinostat et al. (2018) |
|                      | CXCR2, CSF-1R/CSF-1 | | Mok et al. (2014), Kumar et al. (2017a) |
|                      | 5-aza-2'-deoxycytidine | | DuRkin et al. (2010) |
| TAMs                 | LILRB2-SHIP1/2-ERK/P38 | Differentiate to TAM-1 | Gordon et al. (2017) |
|                      | CD47 | Promoting TAM activity | Li et al. (2019) |
| TANs                 | CCL5, CXCL9, CXCL10 | Eosinophils promote TAM-1 differentiation and T cell migration | Eruslanov et al. (2014) |
|                      | CCL3, CCL4 | Basophils promote T cell infiltration | Singhal et al. (2016) |
| Monocytes            | — | Contributes to anti-PD-1/CTLA-4 responses | Carretero et al. (2015); Sektioju et al. (2016) |
| DCs                  | EZH2 | Contributes to anti-PD-1 responses | Bolton et al. (2015) |
2.3 Inflammatory factors participating in extracellular matrix

Cancer ECM is formed through secreted regulators and repressors (Ho et al., 2020). CAFs participate in the process of tumor fibrosis and contribute to the ECM (Jensen et al., 2021). Fibrosis of the ECM through TGF-β signal (Nissen et al., 2019), is considered to be one of the key factors affecting the response to immunotherapy (Bagaev et al., 2021). A combined anti-CTLA-4 and anti-PD1 approach was linked to ECM components to enhance retention within the ECM, suggesting that ECM modulation may be an effective approach to enhance the efficacy of ICIs therapy (Ishihara et al., 2017).

2.3.1 Extracellular matrix formation affects immune cells and inflammatory factors

The formation of ECM determines the migration and localization of immune cells to a certain extent (Hynes, 2009; Hallmann et al., 2015). Based on TME extracellular components, tumors are classified as immune-inflammatory tumors, immune-rejecting tumors, and immune-desert tumors (Hegele and Chen, 2020). Immunorejecting tumors respond worse to ICIs than immunoinflammatory tumors, as T cells are blocked away from the tumor (Tumeh et al., 2014; Chen and Mellman, 2017). First, the dense ECM acts as a physical barrier to hinder the infiltration of TILs. Abundant collagen blocks homing T cells despite being activated (Evanko et al., 2012). Elevated collagen level causes patients to resist anti-PD-1/PD-L1 (Peng et al., 2020). Hyaluronic acid (HA) also prevents the move of effector cells (Jacobetz et al., 2013). Chemokine-dependent T cells were observed to infiltrate restricted due to the dense HA surrounding lung cancer tissue (Salmon et al., 2012). Second, immune cells are regulated by the composition of the ECM (Cooper et al., 2016). Collagen inhibits T cell activity by signaling through SHP-1 (Peng et al., 2020). HA promotes inflammation in the TME and increases Treg activity through TLR signaling (Nikitovic et al., 2015). Matrix metalloproteinases (MMPs) promote tolerance polarization in DCs by binding to TLR2 (Godefroy et al., 2014). Vascular endothelial growth factor (VEGF), which is abundantly present, also has inhibitory effects on DCs (Burbage and Amigorena, 2020). Chondroitin sulfate proteoglycan (VCAN) is directly associated with the reduction of TIL (Gorter et al., 2010), as it prevents T cell adhesion and migration (Peng et al., 2020). Meanwhile, it can also indirectly inhibit CTL infiltration by recruiting MDSCs (Wight et al., 2014) and regulating Batf3 DCs (Hope et al., 2017). Third, some ECM components influence inflammatory factor levels. For example, MMP-9 increases TNF-α, IL-1β, IL-6 levels (Liao et al., 2021). Low doses of collagen synergize with CXCL12 to induce the release of CD40L via p38-MAPK activation (Nakashima et al., 2020). Collagen peptides can significantly inhibit the secretion of IL-1β, TNF-α and PGE2 (Wang et al., 2018b). Thus, type III collagen propeptide is a predictor of metastatic melanoma response to ICIs (Hurkmans et al., 2020), and type IV collagen fragments can also identify melanoma patients who benefit from anti-CTLA-4 (Jensen et al., 2020).

2.3.2 Immune cells and inflammatory factors affect extracellular matrix remodeling

Remodeling of the ECM is thought to be a key factor in response to immune cell trafficking and activation of the immune cycle (Huse, 2017). In bladder cancer patients, PD-L1 expression is discordant at metastatic sites and the primary tumor, suggesting the dynamic nature of the ECM (Mukherji et al., 2016). TGF-β has been reported to increase the synthesis and deposition of type I collagen and downregulate MMP-2 (Türüli et al., 2021). Activation of the RhoA/ROCK signaling pathway and transcription of SNAIL1 and TWIST1 genes are both triggered by TGF-β (Gaggioli et al., 2007; García-Palmero et al., 2016; Chung et al., 2021). At the same time, TGF-βR is also necessary for the deposition of collagen and fibronectin (Shuang and Chakrabarty, 2010; Robert et al., 2018). TNF-α and fibroblast growth factor (FGF)-2 are also important adjuvants in the process of promoting collagen synthesis (Katsumata et al., 2019; Muchová et al., 2021). In contrast, IL-1α/β promotes IL-6 and IL-8 and inhibits ECM, by regulating the expression of Versioncan (Chang et al., 2017; Osei et al., 2020). Interferon regulatory factor 9 regulates VCAN transcription independently of JAK-STAT signaling (Brunn et al., 2021). Immune cells are also involved in engineering ECM components (Bhattacherjee et al., 2019). For example, macrophages produce Hyaluronic Acid Synthase 1 via TLR2 and Syndecan-4 via TLR2, TLR3 and TLR4 (Chang et al., 2017). Also, the M1 macrophages to produce MMP-10 contribute to vascular remodeling through STAT1 signaling (Chi et al., 2022). TGF-β secreted by CD4+ T cells is also involved in vascular reorganization (Li et al., 2020).

2.3.3 Cancer-associated fibroblasts

Activated CAFs often build a matrix-dense barrier in the ECM to protect tumor cells and trap T cells, which affects the efficacy of ICIs (Godefroy et al., 2014). In metastatic urothelial carcinoma patients treated with PD-L1 monoclonal antibody, activated TGF-β signaling pathway in CAFs may hinder T cells from infiltrating tumors (Mariathasan et al., 2018). In co-culture with triple-negative breast cancer, TNF-α and IL-1β induced CXCL8/CCL5 secretion to suppress CD8+ T cells (Libomirski et al., 2019). The resistance of breast cancer bone metastases to ICB is thought to be the release and desorption of TGF-β after osteoclast induction of osteogenesis, reducing the number of TH1 (Jiao et al., 2019). In addition, p-STAT-3, which is associated with metastatic brain tumors, reduces CD8+ T cell activity and increases the abundance of CD74+ macrophages, potentially playing a role in ICIs (Prieo et al., 2018). CAFs have been reported to increase the expression of Fas and PD-1 to control the binding with PD-L2 for the former and Fas ligand for the latter...
Loss of Chitinase-3-like 1 in CAFs also increases the TILs (Cohen et al., 2017). Meanwhile, CAF inhibits NK protein (NKp) 44, 30, DNAX accessory molecule-1 (DNAM-1), and poxivirus receptors (Calon et al., 2014; TomokoInoueKatsuyukiTaguchi et al., 2016), which are the activating receptors of NK cells. High levels of IL-6 secreted by CAFs summon MDSCs and amplify PD-L1 in hepatocellular cancer (Liu et al., 2017). CSF-1 in the TME contributes to the reduction of chemotactic factors in CAFs. CSF-1 receptor and CXCR2 are key items for MDSCs gathering (Kumar et al., 2017b). CTLA-4 antibodies were more effective when combined with the GM-CSF vaccine (van Elsas et al., 1999). CAFs can also secrete other negative factors, such as CXCL12, CCL2, and VEGF (Grum-Schwensen et al., 2005; Chen et al., 2017). CXCL12/CXCL12R helps sensitize to anti-PD-L1 therapy, resulting in T cell aggregation and cancer regression (Feig et al., 2013). In gastric and colon cancers, fibroblast activation protein (FAP) in CAFs leads to more CCL2 and less IFN-γ, eventually damaging the outcome of ICIs therapy (Chen et al., 2017), while FAP Inhibition reverses this resistance (Wen et al., 2017). DNA vaccines against FAP induce activation of CD8+ and CD4+ T cells to enhance responses to ICIs (Xia et al., 2016). A pancreatic cancer analysis showed that TGF-β signaling in CAFs activated "ECM-up" signaling, independent of CAFs or TGF-β activation, a predictor associated with anti-PD-1 resistance, even better than T Cellular inflammatory signaling and mutational burden (Chakravarthy et al., 2018).

Given the complexity and dynamics of the tumor microenvironment, a single biomarker may not be sufficient, and a combination of multiple markers is supposed to be paneled (Binnewies et al., 2018; Kitano et al., 2018). Initial tumor biopsy assessment of PD-L1 abundance, TIL infiltration, and ECM status, combined with longitudinal assessment of changes in each factor during treatment, may have a unique potential to predict tumor phenotypes that respond to ICIs.

3 Inflammatory factors on immune-related adverse effects to immune checkpoint inhibitors in the circulation

Treatment with ICIs induces systemic and local inflammatory responses (Tsukamoto et al., 2018), starting from the interaction between inflammatory factors and their recruitment to immune cells. Inflammatory factors mediate each other. For example, the combination of anti-PD-L1 and anti-IL-6 antibodies increases IFN-γ and Th1 in melanoma mice (Tsukamoto et al., 2018), turning off IL-6/STAT3 pathway, which further activates IFN-γ/STAT1 for causing local inflammation (Xiang et al., 2020). In addition, inflammatory factors contribute to the accumulation of immune cells. TNF-α contributes to Th17 differentiation in colon cancer treated with anti-CTLA-4 (Beck et al., 2006), possibly due to IL-23/Th17 axis activation (Liu et al., 2021). In addition, cosinophils in the skin (Voskens et al., 2013) and macrophages in acute diabetes (Hu et al., 2020) are also the result of the application of ICIs by IFN-α or γ.

Further, the expansion of the inflammatory factor cascade leads to immune damage to normal tissues, which is the main cause of side effects. IrAEs can occur in various organs (Figure 3) and are associated with good responses to ICIs (Saleh et al., 2019). However, an overresponse can hinder the course of ICIs treatment (Saleh et al., 2019), and the presence of severe irAEs leads to discontinuation of ICIs therapy temporarily or permanently according to guidelines. Induction of increased immune-promoting cells, such as a marked expansion of Th17 cells, is an independent risk factor for severe colitis in patients receiving ipilimumab (Tarhini et al., 2015). In contrast, immunosuppressive cells, such as Treg cells, tend to be depleted after treatment with ICIs (Simpson et al., 2013). The influx of myeloid cells also stimulates organ damage (Nam et al., 2019). In addition, different irAEs may have their specific cytokine profiles (Table 2). Circulating baseline IL-17 levels may help predict patients who are likely to develop severe diarrhea and colitis after treatment with ICIs (Young et al., 2018). However, IL-22 was not elevated (Luoma et al., 2020). The inflammatory response in rheumatoid arthritis is often accompanied by abundant TNF-α and IL-6 (Mcinnes et al., 2013).
2016). PD-1 blockade results in increases in IFN-γ, TNF-α, IL-2, 6, 17, and 23 (Dulos et al., 2012; Mcinnes et al., 2016). These changes may trigger psoriasis when treated with PD-1 inhibitors (Murata et al., 2017). However, IL-8 was not associated with dermatitis (Tanaka et al., 2017). In addition, upregulation of CXCL9, CXCL10, and CXCL11 has also been observed to correlate with PD-1 drug-related skin toxicity (Goldinger et al., 2016; Vivar et al., 2017). Prior to treatment, higher concentrations of IL-1β, 2, and GM-CSF were exposed in thyroid irAE (Kurimoto et al., 2020). Anti-TNF monoclonal antibodies prevent colitis (Perez-Ruiz et al., 2019), but at the same time may exacerbate cardiotoxicity associated with ICIs (Kwon et al., 2003) and may exacerbate interstitial lung disease (Akiyama et al., 2016). Pneumonitis, serum sickness, encephalitis, and systemic inflammatory response syndrome were all improved when anti-IL-6 antibodies were used to treat severe IRAE (Stroud et al., 2019). However, it increases the risk of inflammatory bowel disease (Korzenik et al., 2019). Arthritis induced by ICIs can also be ameliorated by inhibition of IL-6 and TNF-α (Sang et al., 2017; Cappelli et al., 2018). Other cytokines, such as IL-12p70, 1α, IRA and 13, IFN-α2, CSF, CX3CL1, and FGF-2, were also differentially expressed in the plasma of severe irAEs patients before and during ICIs treatment (Tarhini et al., 2015), but they The association with specific classes of IRAEs and their associated mechanisms are unclear.

### 4 Conclusion and future perspectives

Less than half of the cases respond to ICIs (Young et al., 2018), and there is a lack of effective predictors. A personalized panel composed of various inflammatory factors is a proposed predictive tool, the main factors including IFN, TLR, IL, TNF-α and TGF-β. They were selected for affecting PD-L1 expression and immune cell infiltration. They not only activate signaling pathways or regulate chemokines but also participate in ECM remodeling or balance pro- and anti-inflammatory effects.

IRAEs occurred more frequently when ICIs treatment was shifted from monotherapy to combination therapy (Johnson et al., 2020). Balancing anti-inflammatory and pro-inflammatory is expected to resolve the dilemma between anticancer and anti-irAEs of ICIs therapy, so some combination drugs have been tried other than glucocorticoids. The first is inflammatory pathway inhibitors. PI3K blockade fights cancer and reduces side effects by silencing inflammatory pathways (Eschweiler et al., 2022). The second is inflammatory factor inhibitors, which have a bidirectional effect. Anti- and pro-inflammatory are regulated by TNF through binding to different receptors (TNFR1 and TNFR2) (Chen et al., 2021), and by IL-6 through activation of different signals (JAK-STAT3 or PI3K-Akt) (Nguyen et al., 2014). The third is small molecule inhibitors of immune checkpoints and nanoparticles (Zhang et al., 2019). Small-molecule inhibitors can reduce affinity to reduce IRAEs, while nanoparticles facilitate targeting to improve anticancer efficacy.

The influence of inflammatory factors is not only applicable to ICIs treatment, but also to other immunotherapies. Immune-related side effects are triggered consistently across various immunotherapies, all resulting from cytokine cascades (Weber et al., 2015). For example, in adaptive immune cell therapy, IL-6, IL-1 are the
main triggers of cytokine release syndrome. Likewise, upregulated IFN and IL-2 caused gastrointestinal reactions and thyroid damage during cytokine therapy. Due to the universality of the effects and side effects of inflammatory factors in various immunotherapies, the understanding of inflammatory factors in ICIs may be extended to immunotherapy in pan-cancer and benefit more patients.

Author contributions

YW did the literature research and wrote the article. SY and HQ revised the manuscripts. All authors read and approved the final manuscript.

References

Abiko, K., Matsumura, N., Haminishi, J., Horikawa N., Multakami, R., Yamaguchi, K., et al. (2015). IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112 (9), 1501–1509. doi:10.1038/bjc.2015.101

Abril-Rodriguez, G., and Ribas, A. (2017). SnapShot: Immune checkpoint inhibitors. Cancer Cell 31 (6), 848. doi:10.1016/j.ccell.2017.03.010

Akiyama, M., Kanelo, Y., Yamaoka, K., Kondo, H., and Takeuchi, T. (2016). Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: A retrospective, case-control study. Rheumatol. Int. 36, 881–889. doi:10.1007/s00296-016-3478-3

Arakawa, A., Vollmer, S., Tietje, J., Galinski, A., Hepp, M. V., Burdek, M., et al. (2019). Glioblastoma of CD4+ blood T cells predicts longer survival with CTLA4 or PD-1 checkpoint inhibition in advanced melanoma. Front. Immunol. 10, 1356. doi:10.3389/fimmu.2019.01336

Baas, M., Besançon, A., Gonzáles, T., Valette, F., Yagita, H., Sawitoksi, B., et al. (2016). TGFB-dependent expression of PD-1 and PD-L1 controls CD8+ T cell emergence in transplant tolerance[[1]]. Elife 5, e08113. doi:10.7554/eLife.08113

Bagare, A., Kodov, N., Nomac, K., Svekolkin, V., Gusarov, A., Isaeva, O., et al. (2021). Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39 (6), 845–865.e7. doi:10.1016/j.ccell.2021.04.014

Bagchi, S., Yuan, R., and Engleman, E. G. (2021). Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16 (1), 233–249. doi:10.1146/annurev-pathol-042020-0402741

Basse, A., Vos, H., Van Dyck, L., Flores, G., Ariz, I., Desmedt, C., et al. (2021). A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 27 (5), 820–832. doi:10.1038/s41591-019-02312-8

Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., et al. (2006). Enterocolitis in patients with cancer after antibody blockade of cytotoxic T lymphocyte-associated antigen 4. J. Clin. Oncol. 24 (15), 2293–2289. doi:10.1200/JCO.2005.04.5716

Belucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., et al. (2015). Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor ltration and metastasis. J. Immunol. 205 (10), 6090–6098. doi:10.4049/jimmunol.1500884

Benghui, D., Santos, S. J. B., Backe, H. J., Tamaniu, A. H., Egerer, R. M., Schilham, M. W., et al. (2011). Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression. J. Pathol. 223, 347–357. doi:10.1002/path.2819

Berner, F., Bomze, D., Diem, S., Ali, O. H., Fassler, M., Ring, S., et al. (2019). Association of checkpoint inhibitor-induced toxic effects with shared cancer and inflammatory arthritis differs by immunotherapy regimen[[1]]. Seminars Arthritis Rheumatism 48 (3), 553–557. doi:10.1016/j.semarthrit.2018.02.011

Carbotti, G., Gargini, A., Airola, I., Mezzanzanca, D., Bagnoli, M., Ferrero, S., et al. (2015). IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget 6 (41), 45267–45280. doi:10.18632/oncotarget.6530

Caroline, R., Long, G. V., Brady, D., Dutriaux, C., Maio, M., Mortier, L., et al. (2015). Nivolumab versus docetaxel in advanced non-small-cell lung cancer. N. Engl. J. Med. Overseas. Ed. 373, 1627–1639. doi:10.1056/nejmoa1507643

Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P., and De Carvalho, D. D. (2016). TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat. Commun. 9 (1), 4692. doi:10.1038/ncomms10654

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Wu et al. 10.3389/fphar.2022.990445

Chang, M. Y., Kang, I., Gale, M., Manicone, A. M., Kinsella, M. G., Braun, K. R., et al. (2017). Versican is produced by Traf- and type I interferon-dependent signaling in macrophages and contributes to fine control of innate immunity in lungs. Am. J. Physiol. Lung Cell. Mol. Physiol. 313 (6), L1069–L1086. doi:10.1152/ajplung.00333.2017

Chen, A. Y., Wolchok, J. D., and Bass, A. R. (2021). TNF in the era of immune checkpoint inhibitors: Friend or foe?[J]. Nat. Rev. Rheumatol. 17 (4), 213–223. doi:10.1038/s41584-021-00554-4

Evanko, S. P., Potter-Pergo, S., Bolhky, P. L., Nepom, G. T., and Wight, T. N. (2012). Hyaluronan and versican in the control of human T lymphocyte adhesion and migration. Matrix Biol. 31 (2), 90–100. doi:10.1016/j.matbio.2011.10.004

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., et al. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (10030), 1837–1846. doi:10.1016/S0140-6736(16)30587-0

Feng, C., C. O., J., Kraman, M., Wells, R. B., Deonarine, A., Chan, D. S., et al. (2013). Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 110 (50), 20212–20217. doi:10.1073/pnas.1320318110

Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S., et al. (2010). CCL2 blockade augments cancer immunotherapy. Cancer Res. 70 (1), 109–118. doi:10.1158/0008-5472.CAN-09-2326

Friedline, R. H., Brown, D. S., Nguyen, H., Kornfield, H., Lee, J., Zhang, Y., et al. (2009). CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J. Exp. Med. 206 (2), 421–434. doi:10.1084/jem.20081811

Fujita, M. (2021). EGGC inhibits tumor growth in melanoma by targeting JAK-STAT signaling and its downstream PD-L1/PD-L2 axis in tumors and enhancing cytotoxic T-cell infiltrates. Front. Immunol. 12, 151. doi:10.3389/fimmu.2021.657918

Garabliolu, D. I. (2017). Myeloid-derived suppressor cells. Cancer Immunol. Res. 5 (1), 3–8. doi:10.1158/2326-6066.CIR-16-0297

Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J. F., Harrington, K., et al. (2007). Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9 (12), 1392–1400. doi:10.1038/nca.2007.165

Gang, H., Qianjun, W., Yongliang, Z., Qiangguo, G., Yun, B., et al. (2013). NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment[J]. PLoS One 8 (4), e61602.

Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodrigues, G. A., et al. (2017). Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19 (6), 1189–1201. doi:10.1016/j.celrep.2017.04.031

Garcia-Palmero, I., Torres, S., Bartolomé, R. A., Peral-Agraicea, A., Larríba, M. J., Lopez-Luzon, D., et al. (2016). Twist-induced activation of human fibroblasts promotes matrix stiffness by upregulating palladin and collagen al(V). Oncogene 35 (40), 5254–5263. doi:10.1038/onc.2016.57

Goldreyro, E., Gallois, A., Ildaya, J., Merad, M., Nung, M., Nonu, N., et al. (2014). Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. Cell Rep. 9 (5), 1856–1870. doi:10.1016/j.celrep.2014.10.067

Goldinger, S. M., Steiger, P., Meier, B., Micalioto, S., Contassot, E., French, L. E., and Lopez-Lazord, L. (2015). Cytokine-mediated cutaneous drug reactions during anti-PD-1 therapy. Clin. Cancer Res. 21 (20), 5203–5212. doi:10.1158/1078-0432.CCR-15-2872

Gordon, S. R., Maule, R. L., Dulk, B. W., Hutter, G., George, B. M., McCracken, M. N., et al. (2017). PD-1 expression in the control of human T lymphocyte apoptosis, phagocytosis and tumour immunity. Nature 545 (7655), 495–499. doi:10.1038/nature22396

Gorter, A., Zilman, J. H., van Gent, H., Trimbos, J. B., Heuven, G. J., and Jordonav, E. S. (2010). Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. Med. Pathol. 23 (12), 1605–1615. doi:10.1097/MOP.0b013e3181f9cda0

Gowrishankar, K., Gunalatke, D., Gallagher, S. J., Tiffen, J., Rizos, H., and Hersey, P. (2015). Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB[J]. PLoS One 10 (4), e0123410. doi:10.1371/journal.pone.0123410

Grum-Schwensen, B., Klingelhofer, J., Berg, C. H., El-Naasam, C., Gregorion, M., Lukainan, E., et al. (2005). Suppression of tumor development and metastasis formation in mice lacking the S100A8/m13 gene. Cancer Res. 65 (9), 3772–3780. doi:10.1158/0008-5472.CAN-04-1450

Hallmann, R., Zhang, X., Di Russo, J., Li, S., Song, J., Hannoeks, M. J., et al. (2015). The regulation of immune cell trafficking by the extracellular matrix. Curc. Opin. Cell. Biol. 36, 54–61. doi:10.1016/j.ceb.2015.06.006

Han, N., Li, X., Wang, Y., Wang, L., Zhang, C., Zhang, Z., et al. (2021). Increased tumour-infiltrating plasmacytoid dendritic cells promote cancer cell proliferation and invasion via TNF-α/NF-kB/CXCR4 pathway in oral squamous cell carcinoma. J. Cancer 12 (10), 3045–3056. doi:10.7150/jca.55580

Eschweiler, S., Ramirez-Suátegui, C., Li, Y., King, E., Chudley, L., Thomas, J., et al. (2022). Intermediary PTK6 inhibition sustains anti-tumour immunity and curbs irAEs. Nature 605 (7911), 741–746. doi:10.1038/s41586-022-04665-2

Evanko, S. P., Potter-Pergo, S., Bolhky, P. L., Nepom, G. T., and Wight, T. N. (2012). Hyaluronan and versican in the control of human T lymphocyte adhesion and migration. Matrix Biol. 31 (2), 90–100. doi:10.1016/j.matbio.2011.10.004

Eppihimer, M. J., Green, F. J., Greenfield, E. A., Chernova, T., Erickson, J., et al. (2015). Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 22 (9), 133–145. doi:10.1111/micr.1200032.2013

Erasuloan, E. B., Bhognagarwala, P. S., Quatromoni, J. G., Stephen, T. L., Ranganathan, A., Deshpande, C., et al. (2014). Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Invest. 124 (12), 5466–5480. doi:10.1172/JCI77053

Frontiers in Pharmacology | www.frontiersin.org 11 June 2023 | Volume 14 | Article 109530 | Wu et al. 10.3389/fphar.2022.990445
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slighuff, C., et al. (2009). Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69 (7), 3077–3085. doi:10.1158/0008-5472.CAN-08-2281

Hart, K. M., Byrne, K. T., Molloy, M. J., Usherwood, E. M., and Berwin, B. (2011). IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front. Immunol. 2, 29. doi:10.3389/fimmu.2011.00029

Haslam, A., and Prasad, V. (2019). Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2 (5), e192535. doi:10.1001/jamanetworkopen.2019.2355

Hegde, P. S., and Chen, D. S. (2020). Top 10 challenges in cancer immunotherapy. Immunity 52, 17–35. doi:10.1016/j.immuni.2019.12.011

Hoo, Y. J., Li, J. P., Fan, C. H., Liu, H. L., and Yeh, C. K. (2020). Ultrasound in tumor immunotherapy: Current status and future developments. J. Control. Release 323, 23–123. doi:10.1016/j.jconrel.2020.04.023

Hope, C., Emmerich, P. B., Papadis, A., Pagenkopf, A., Matkowskyj, K. A., Van De Hey, D. R., et al. (2017). Versican-derived matrixin regulators batf3-dendritic cell differentiation and promote T-cell infiltration in colorectal cancer. J. Immunol. 199 (5), 1933–1949. doi:10.4049/jimmunol.1700529

Hopkins, A. C., Yarchosan, M., Durham, J. N., Yusko, E. C., Rytlowska, J. A., Robins, H. S., et al. (2018). T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. Clin. Cancer Res. 25 (3), 122092. doi:10.1158/2326-6066.CCR-17-2129.4

Hsu, H., Zakhvor, P. N., Peterson, O. J., and Unanue, E. R. (2020). Cytocidal brils. Immunity 52, 17–35. doi:10.1016/j.immuni.2020.04.023

Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., et al. (2018). Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of inflammatory antibodies. Sci. Adv. 5 (11), eaay1971. doi:10.1126/sciadv.aay1971

Kagamuto, H., Kito, S., Otsuka, A., Yasumura, K., Racy, M. M., Yuba, E., et al. (2019). CD4+ T-cell immunosuppressive by induction of B7-1/11. Leukoc. Blood 89 (6), 837–845. doi:10.1189/jlb.1209788

Karanikolas, S., Hitak, S., Karr, A., and Mathiak, K. (2011). IL-27 renders DCs non-responding to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther. Adv. Med. Oncol. 10, 1758841717749748. doi:10.1177/1758841717749748

Kim, S. H., Oh, J., Choi, J. Y., Jang, J. Y., Kang, M. W., and Lee, C. E. (2008). Identification of human thioredoxin as a novel IFN-γ-induced factor: Mechanism of induction and its role in cytokine production. BMC Immunol. 9, 64. doi:10.1186/1471-2474-9-64

Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., et al. (2008). The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 180 (10), 6738–6746. doi:10.4049/jimmunol.180.10.6738

Kitsos, S., Nakayama, T., and Yamashita, M. (2018). Biomarkers for immune checkpoint inhibitors in melanoma. Front. Oncol. 8, 270. doi:10.3389/fonc.2018.00270

Ko, S. S., Zea, A. H., Rini, B. L., Ireland, J. L., Elson, P., Cohen, P., et al. (2009). Sunlight mediates reversal of myeloid-suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148–2157. doi:10.1158/1078-2277.CCR-08-1332

Kondo, A., Yamashita, T., Tamura, H., Zhao, W., Tsuj, T., Shimizu, M., et al. (2010). IFN-γamma and tumor necrosis factor alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB and activation in blasts in myelodysplastic syndromes. Blood 116 (7), 1124–1131. doi:10.1182/blood-2009-12-255125

Korzenik, J. R., Larsen, M. D., Nielsen, J., Kjeldsen, J., and Norgard, B. M. (2019). Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than in inflammatory bowel disease. Aliment. Pharmacol. Ther. 50, 289–294. doi:10.1111/apt.15370

Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., et al. (2018). High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat. Med. 24 (2), 144–153. doi:10.1038/nm.4466

Kumar, V., Donthireddy, L., Marvel, D., Condimane, T., Wang, F., Lavilla-Alonso, S., et al. (2017). Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors[J]. Cancer Cell 32 (5), 654–668. e5. doi:10.1016/j.cccel.2017.10.005

Kumar, V., Donthireddy, L., Marvel, D., Condimane, T., Wang, F., Lavilla-Alonso, S., et al. (2017). Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32 (5), 654–668. doi:10.1016/j.cccel.2017.10.005

Kurokito, C., Inaba, H., Ariyasa, H., Iwakura, H., Ueda, Y., Uralu, S., et al. (2020). Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 111, 1468–1477. doi:10.1111/cas.14363

Kwon, H. J., Cote, T. R., Cuffe, M. S., Kramer, J. M., and Braun, M. M. (2003). Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138 (8), 807–811. doi:10.7326/0003-4819-138-10-20030500-00008

Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., and Shields, J. D. (2018). Cancer-associated fibroblasts induce antigen-specific depletion of CD8+ T cells to protect tumour cells. Nat. Commun. 9 (4), 948. doi:10.1038/s41467-018-03374-0

Li, B., Song, T. N., Wang, F. R., Yin, C. L., Li, Z., Lin, J. P., et al. (2019). Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1+ TAM expansion. Oncogene 38 (3), 17. doi:10.1038/s41389-019-0126-2

Li, S., Liu, M., Do, M. H., Chou, C., Stamatides, E. G., Nixon, B. G., et al. (2020). Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells. Nature 587 (7832), 121–125. doi:10.1038/s41586-020-2805-3
Wu et al. (2018). TGF-

Messer, M. N., Netherby, C. S., Banki, D., and Abrams, S. I. (2015). Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol. Immunother. 64, 1–13. doi:10.1007/s00262-014-1639-3

Meyer, C., Cagon, L., Costa-Nunes, C. M., Baumgertner, P., Montandon, N., Levrau, L., et al. (2014). Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247–257. doi:10.1007/s00262-013-1508-5

Mezzadra, R., Chong, S., Jee, L. T., Gomez-Eisenreich, R. d., van Beveren, W., Wu, et al. (2017). Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549 (7670), 106–110. doi:10.1038/nature23669

Mok, S., Koya, R. C., Xu, C., Xu, J., Robert, L., Wu, et al. (2014). Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 74, 153–161. doi:10.1158/0008-5472.CAN-13-1816

Muchová, J., Heurnden, V., Micholovská, L., Vistejnova, L., Zavadováka, A., Smírková, K., et al. (2021). Mutual influence of selenium nanoparticles and FGFE2-stab on biocompatible properties of collagen/chitosan 3D scaffolds. In vitro and ex vivo evaluation. J. Nanobiotechnology 19, 1. doi:10.1186/s12951-021-00849-w

Muñoz, J., Babbour, M. N., Saroum, M., Temraza, S., Nair, R., Charafeddine, M., et al. (2016). Programmed death ligand 1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: A reliable treatment selection biomarker? Clin. Genitourin. Cancer 14, 183–187. doi:10.1016/j.cgc.2015.12.002

Murata, S., Kaneko, S., Harada, Y., Aoi, N., and Morita, E. (2018). Case of de novo psoriasis possibly triggered by nivolumab. J. Dermatol. 44, 99–100. doi:10.1680/jderm.1141883.13450

Muthuswamy, R., Cormar, J. M., Dahl, K., Chatta, G. S., and Kalinski, P. (2016). Functional reprogramming of human prostate cancer to promote local attraction of effector CD8+ T cells. Prostate 76 (12), 1095–1105. doi:10.1002/pros.23194

Na, L., Formisano, L., Gonzalez-Ericsson, P. I., Sanchez, V., Dean, P. T., Opaljenik, S. R., et al. (2018). Melanoma response to anti-PD-L1 immunotherapy requires [AKI signaling, but not [AKI]. Immunology 7 (3), e413806.

Nagaraju, S., Gupta, K., Pravert, V., Kirnarsky, L., Sherman, S., Kang, L., et al. (2007). Altered recognition of antigen is a mechanism of CD28+ T cell tolerance in cancer. Nat. Med. 13, 828–835. doi:10.1038/nm1609

Nakashima, D., Onuma, T., Tanabe, K., Kito, Y., Uematsu, K., Mizutani, D., et al. (2020). Synergistic effect of collagen and CXCL12 in the low doses on human placental activation. PLoS One 15 (10), e0241139. doi:10.1371/journal.pone.0241139

Nam, S., Lee, A., Lim, J., and Lim, J. S. (2019). Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (MDSCs). J. Immunol. Res. 2019, 621. doi:10.1182/blood-2011-07-365825

Ni, X. Y., Sui, H. X., Liu, Y., Ye, K. S. Z., Wang, Y. N., and Gao, F. (2012). TGF-beta of lung cancer microenvironment upregulates B7H1 and GILT expression in dendritic cells and is associated with regulatory T cell generation.[D] Oncol. Rep. 28, 615–621. doi:10.3892/or.2012.1822

Nikitovic, D., Trzaski, M., Berdaki, A., Tsatsakis, A., and Tzanakakis, G. N. (2015). Cancer microenvironment and infiltration: Role of hyaluronan. Front. Immunol. 6, 63. doi:10.3389/fimmu.2015.01619

Nissen, N. I., Karsdal, M., and Willumsen, N. (2019). Collagen and associated fibroblasts in the reactive stroma and its relation to Cancer biology. J. Exp. Clin. Cancer Res. 38 (1), 115. doi:10.1186/s13046-019-1110-6

Noguchi, T., Ward, J. P., Gubin, M. M., Arnold, C. D., Lee, S. H., Hundal, J., et al. (2017). Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol. Immunother. 66, 106–117. doi:10.1007/s00262-016-1606-6

CIR-16-0391

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. (2021). Epithelial-interleukin-1 inhibits collagen formation by airway fibroblasts. Implications for asthma. Sci. Rep. 10 (1), 8721. doi:10.1038/s41598-020-65567-z

Ochi, E. T., Motaço-Giakhin, L., Haier, A., Warner, S. M., Al-Fouad, M., Wang, M., et al. (2020). Epithelial-interleukin-1 inhibits collagen formation by airway fibroblasts.
Sabe, K., Khalife-Saleh, N., and Kourie, H. R. (2019). Do immune-related adverse events correlate with response to immune checkpoint inhibitors? Immunotherapy 11, 257–259. doi:10.2172/anti-2018-0201
Salmon, H., Franciszekiewicz, K., Damotte, D., Dieu-Nojes, M. C., Validere, P., Trautmann, A. (2021). Mx1 architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122 (3), 899–910. doi:10.1172/JCI45817
Sang, T., Tayar, J., Trinh, V. A., Suarez-Almazor, M., Garcia, S., Hwu, P., et al. (2017). Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: A case series. Ann. Rheum. Dis. 76, 2061–2064. doi:10.1136/annrheumdis-2017-211560
Schreiner, B., Mundschoer, M., Kieseier, B. C., Chen, L., Hartung, H. P., Weller, M., et al. (2004). Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation. Relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol. 155 (1-2), 172–182. doi:10.1016/j.jneuroim.2004.06.013
Setoguchi, I. M., Carretiero, R., Bulbec, N., Bald, T., Tuttin, T., Rudensky, A. Y., et al. (2016). Basophils promote tumor rejection via chemokinesis and infiltration of CD8+ T cells. Cancer Res. 76, 291–302. doi:10.1158/0008-5472.CAN-16-0993
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., et al. (2013). Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32–42. doi:10.1158/2326-6066.CIR-13-0013
Shau, N., Arslanoglu, O. T., Gu, Z., and Allison, J. P. (2021). LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy.[J]. J. Exp. Med. 219 (7), e2021811. doi:10.1084/jem.2021811
Sharpe, A. H., Wherry, E. J., Ahmed, R., and Freeman, G. J. (2007). The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Rev. Immunol. 8 (3), 239–245. doi:10.1038/nri2143
Shuang, H., and Chakrabarty, S. (2010). Regulation of fibroblast and laminin receptor expression, fibroblast and laminin secretion in human colon cancer cells by transforming growth factor-beta 1. Int. J. Cancer 57 (3), 742–746. doi:10.1002/ijc.291070522
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., et al. (2019). Intratumoral TGFβ1/PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunology 50 (1), 195–211. doi:10.1111/imn.13024
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepúlveda, M. A., Bergerhoff, K., Arce, F., et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695–1710. doi:10.1084/jem.20130579
Singhal, S., Bhojnagarwala, P. S., O’Brien, S., Moon, E. K., Garfall, A. L., Rao, A. S., et al. (2016). Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer.[J]. Cancer Cell 30, 120–135. doi:10.1016/j.ccell.2016.06.001
Schoelckly, J. T., Dougan, M., Ingram, J. R., Ho, C. M., Kauke, M. J., Almo, C. S., et al. (2016). Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc. Natl. Acad. Sci. U. S. A. 113 (19), E2646-E2654. doi:10.1073/pnas.1602468113
Song, S., Yuan, P., Wu, P., Chen, J., Fu, J., Li, P., et al. (2014). Dendritic cells with an increased PD-L1 by TGFβ1 induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells. Int. Immunopharmacol. 20 (1), 117–123. doi:10.1016/j.intimp.2014.02.027
Steel, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., et al. (2016). CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29, 832–845. doi:10.1016/j.ccell.2016.04.014
Stefani, S., Riyue, B., and Gajewski, T. F. (2015). Melanoma-intrinsic β-catenin signalling prevents antitumour immunity.[J]. Nature 523 (7559), 231–235
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addappali, S., et al. (2019). Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J. Oncol. Pharm. Pract. 25 (3), 351–357. doi:10.1177/1078155217745144
Subrahmanyan, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Servignini, M., Zhou, J., et al. (2018). Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J. Immunother. 46 (1), 18. doi:10.1097/JIM.00000000000003828

Frontiers in Pharmacology frontiersin.org
activating NK receptor. cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of programmed death ligand 1 (PD-L1) expression in triple negative breast cancer suppressive T cells: Induction of autoimmune disease by breaking their anergic/immunotherapy.

Wu et al. 10.3389/fphar.2022.990445

activating NK receptor. cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of programmed death ligand 1 (PD-L1) expression in triple negative breast cancer suppressive T cells: Induction of autoimmune disease by breaking their anergic/immunotherapy.

Wu et al. 10.3389/fphar.2022.990445

activating NK receptor. cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of programmed death ligand 1 (PD-L1) expression in triple negative breast cancer suppressive T cells: Induction of autoimmune disease by breaking their anergic/immunotherapy.

Wu et al. 10.3389/fphar.2022.990445

activating NK receptor. cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of programmed death ligand 1 (PD-L1) expression in triple negative breast cancer suppressive T cells: Induction of autoimmune disease by breaking their anergic/immunotherapy.

Wu et al. 10.3389/fphar.2022.990445

activating NK receptor. cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of programmed death ligand 1 (PD-L1) expression in triple negative breast cancer suppressive T cells: Induction of autoimmune disease by breaking their anergic/immunotherapy.

Wu et al. 10.3389/fphar.2022.990445

activating NK receptor. cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of programmed death ligand 1 (PD-L1) expression in triple negative breast cancer suppressive T cells: Induction of autoimmune disease by breaking their anergic/immunotherapy.

Wu et al. 10.3389/fphar.2022.990445